Eluceda has today called on the government for an urgent £2
million funding grant to rollout a transformative technology that will rapidly
reduce Coronavirus (COVID-19) detection times.
Eluceda’s cutting-edge technology reduces the screening time for the Coronavirus (COVID-19) from the current rate of around three days to just 20 minutes. Using the technology, one lab technician would be able to carry-out around 20 tests per hour meaning the mass screening of suspected patients would be more viable.
At a cost of around £2 million, the new technology could be developed and deployed nationwide within three months.
The existing screening method to detect Coronavirus relies heavily on two strategies. First, a symptomatic assessment -- whether the individual has a cough, high temperature, or shortness of breath. Second, a quantitative assessment based on quantitative real-time reverse transcription polymerase chain reaction (qRT-PCR), dubbed the “Gold Standard”.
The gold standard is complex and requires samples to be sent to a handful of nominated laboratories. This process takes days, meaning it is unable to meet the requirements for high-flux quarantine and is unsuitable for the early treatment of infected patients.
Eluceda’s new patented testing technology can detect bacteria and viruses more quickly. It works by first extracting the DNA/RNA from the cells of the sample taken and then detecting the exact match of DNA/RNA using a corresponding sequence that has been anchored to a custom biosensor electrode.
The Eluceda test is currently being developed into an automated device. Eluceda can adapt its existing technology to detect the specific RNA sequence of the Coronavirus (COVID-19) within an estimated 3 months.
The cost to develop this test would require the entire Eluceda business to focus on developing this test at a cost of around £2 million but could be started immediately with the available RNA sequence of the virus.
Commenting, Matthew Harte, Managing Director of Eluceda said:
“Early detection and diagnosis are critical in the global fight against SARS-CoV-2 (COVID-19). Eluceda’s unique new technology, designed and developed here in Britain, further embeds the UK’s place on the front line in the development of new technologies that can help in that struggle and in so doing save countless lives.
Our technology is transformative. It can significantly reduce the screening time for SARS-CoV-2 (COVID – 19) from the current rate of around three days down to just twenty minutes. It means as many as twenty suspected patients can be screened, accurately, by one laboratory technician within 60 minutes. Such a dramatic reduction in the time taken between testing and accurate diagnosis heavily bolsters the ability for health authorities around the world to reduce the rate of infection and, hopefully, draw an end to this devastating virus.
But we need the Government’s help. We are calling on the health authorities here in the UK to provide us with the urgent investment we need to finalise development and put the technology into mass production.”
ENDS
Challenge us! We want to know the problems you are facing so that we can provide the perfect solution.